Celadon Pharmaceuticals reaffirms its patient-centred approach, advancing cannabis-based medicines through innovation, regulatory excellence, and MHRA-licensed research. Focused on limited-treatment conditions, the UK company aims to deliver safe, effective, evidence-based therapies that improve patients’ quality of life.
-- Celadon Pharmaceuticals, a leading British pharmaceutical company dedicated to advancing cannabis-based medicines, today reaffirmed its commitment to placing patients at the heart of its research and development strategy.
The company continues to concentrate its R&D efforts on key therapeutic areas where patients face limited treatment options. By leveraging its MHRA licensed facility and pharmaceutical expertise, Celadon is advancing the understanding of how cannabinoids can play a transformative role in modern medicine.
“Celadon’s mission has always been defined by patient impact rather than market noise,” said a company spokesperson. “Our focus remains on science, innovation and the responsible development of therapies that can improve lives.”
Celadon’s state-of-the-art facility provides a robust platform for pharmaceutical-grade research and development, underpinned by a team of specialists working to the highest standards of safety and compliance. This capability reinforces the company’s role as a frontrunner in the evolving UK cannabis medicines sector.
While recognising the challenges faced across the wider life sciences landscape, Celadon maintains that innovation, regulatory excellence and patient outcomes remain at the core of its operations. By focusing on advancing cannabinoid science, the company continues to strengthen its position as a trusted innovator.
“As the landscape for cannabis-based medicines develops, our priority is to ensure patients benefit from therapies that are accessible, effective and evidence-based,” the spokesperson added. “Celadon is uniquely positioned to help shape the future of this important sector.”
Celadon Pharmaceuticals remains steadfast in its mission: improving quality of life for patients most in need by developing breakthrough cannabis-based medicines.
About Celadon Pharmaceuticals
Celadon Pharmaceuticals is a UK based pharmaceutical company focused on the research, development and production of cannabis-based medicines. Operating from an MHRA licensed facility, Celadon is committed to advancing safe, effective and evidence based therapies for conditions where patients face limited treatment options. With a strong emphasis on regulatory compliance, innovation and patient outcomes, Celadon is recognised as one of the leading innovators shaping the future of cannabinoid-based medicine in the UK.
Contact Info:
Name: Press and Media
Email: Send Email
Organization: Celadon Pharmaceuticals
Website: https://celadonpharma.com/
Release ID: 89168518
In case of identifying any errors, concerns, or inconsistencies within the content shared in this press release that necessitate action or if you require assistance with a press release takedown, we strongly urge you to notify us promptly by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team is committed to addressing your concerns within 8 hours by taking necessary actions diligently to rectify any identified issues or supporting you with the removal process. Delivering accurate and reliable information remains our top priority.
